<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080740</url>
  </required_header>
  <id_info>
    <org_study_id>YPH-BV</org_study_id>
    <nct_id>NCT03080740</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis</brief_title>
  <official_title>The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Yipinhong Pharmaceutical CO.,LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Yipinhong Pharmaceutical CO.,LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, positive drug parallel comparison, multi-centre clinical trial to
      assess the Efficacy and Safety of Clindamycin palmitate hydrochloride dispersible tablet for
      the treatment of bacterial vaginosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment group: Clindamycin palmitate hydrochloride dispersible tablet . Control group:
      Metronidazole Tablet.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nugent score</measure>
    <time_frame>From the first day of randomization to 4-10 and 23-33 days after the end,expected to be up to 33 days.Evaluate changes from baseline to the end of the study.</time_frame>
    <description>score of Vaginal secretions for Gram stain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pH of vaginal secretions;</measure>
    <time_frame>From the first day of randomization to 4-10 and 23-33 days after the end,expected to be up to 33 days.Evaluate changes from baseline to the end of the study.</time_frame>
    <description>pH value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leucorrhea routine examination</measure>
    <time_frame>From the first day of randomization to 4-10 and 23-33 days after the end,expected to be up to 33 days.Evaluate changes from baseline to the end of the study.</time_frame>
    <description>Vaginal cleanliness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itching score</measure>
    <time_frame>From the first day of randomization to 4-10 and 23-33 days after the end,expected to be up to 33 days.Evaluate changes from baseline to the end of the study.</time_frame>
    <description>The severity of vulvar itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal secretions</measure>
    <time_frame>From the first day of randomization to 4-10 and 23-33 days after the end,expected to be up to 33 days.Evaluate changes from baseline to the end of the study.</time_frame>
    <description>The amount of secretions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Clindamycin palmitate hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin palmitate hydrochloride dispersible tablet</intervention_name>
    <description>300mg, oral after meal, twice daily, a total of 7days</description>
    <arm_group_label>Clindamycin palmitate hydrochloride</arm_group_label>
    <other_name>No other Names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Tablet</intervention_name>
    <description>400mg, oral after meal , twice daily, a total of 7days</description>
    <arm_group_label>Metronidazole</arm_group_label>
    <other_name>No other Names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients clinically diagnosed with bacterial vaginosis, should meet the following
             criteria: vaginal Gram stain integration score (Nugent score) â‰¥7 points

          2. Female patients aged 18 to 55 years old.

          3. Patients signed the Informed Consent Form(ICF).

        Exclusion Criteria:

          1. Patients with vulvovaginitis caused by other infectional reasons such as vaginitis
             vulvovaginal candidiasis, trichomoniasis vaginitis.

          2. Patients received systemic or vaginal antimicrobial therapy in a week before enrolled.

          3. Patients with other vaginal or vulvar disorders which could effect the evaluation of
             efficacy.

          4. Pregnant or lactating patients.

          5. Menopausal women.

             Menopause definition: perimenopausal women stop menstruations for a year.

          6. Women with diabetes.

          7. Dependent on alcohol and could not prohibit during the study period.

          8. Women with liver and kidney disfunction, blood disorders, mental illness or other
             serious diseases.

          9. Women allergic to metronidazole, clindamycin.

         10. With poor compliance.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaohui Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shangrong Fan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Long Sui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Gynecology and Obstetrics Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruifang An, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Xi 'an jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaohui Liu, MD</last_name>
    <phone>+86-10-66174284</phone>
    <email>23662161@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dai Zhang, MD</last_name>
    <phone>+86-10-66174284</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University first hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Liu, MD</last_name>
      <phone>+86-10-66174284</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

